Goal of the second-line therapy among HIV-1-infected patients is to re-establish virological suppression, although treatment options in resource-limited settings are limited. An observational cohort of patients with first-line antiretroviral therapy (ART) failure was conducted in a university hospital in Thailand. Of 95 patients, mean age 39 years, 65% were male. Median CD4 and HIV-1 RNA at second-line ART initiation were 158 cells/mm3 and 4.1 copies/mL, respectively. Boosted protease inhibitor plus 2 nucleoside reverse transcriptase inhibitors (NRTIs), indicated by genotype results, was commonly used as second-line regimen. At 6, 12, 24, and 36 months of second-line ART, 67%, 62%, 84%, and 90% of patients achieved HIV-1 RNA <50 copies/mL; median CD4 were 258, 366, 444, and 522 cells/mm 3, respectively. Good adherence, high baseline CD4, and early Centers for Centers for Disease Control and Prevention (CDC) staging were associated with virologic success (P < .05). Second-line ART based on the results of genotype testing yields the good virologic and immunologic outcomes in a resource-limited setting, and scaling-up of second-line ART is indicated.
Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860.
2.
Montaner JS, Reiss P., Cooper D., et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, The Netherlands, Canada and Australia study. JAMA. 1998;279(12): 930-937.
3.
Manosuthi W. , Chottanapand S., Thongyen S., Chaovavanich A., Sungkanuparph S.Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006 ; 43(1):42-46.
4.
Reniers G., Araya T., Davey G., et al. Steep declines in population-level AIDS mortality following the introduction of antiretroviral therapy in Addis Ababa, Ethiopia. AIDS.2009;23(4):511-518.
5.
Jongwutiwes U., Kiertiburanakul S., Sungkanuparph S.Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res. 2007;5(3):355-360.
6.
Sungkanuparph S., Chakriyanuyok T., Butthum B.Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome. J Infect. 2008;56(1):40-43.
7.
World Health Organization.Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents -November 2009; 1-24. Available at http://www.who.int/HIV/pub/arv/rapid_advice_art.pdf. Accessed on April 16, 2010.
8.
Unaids.2008Report on the global AIDS epidemic. Available at http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008. Accessed on April 16, 2010.
9.
Zhou J., Paton NI, Ditangco R., et al. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med. 2007;8(1):8-16.
10.
Humphreys E. , Hernandez LB, Rutherford G.Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. Cochrane Database Syst Rev.2007;4(17):CD006517.
11.
Sungkanuparph S., Manosuthi W., Kiertiburanakul S., Piyavong B., Chumpathat N., Chantratita W.Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis. 2007;44(3):447-452.
12.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf . Accessed on April 16, 2010.
13.
Gazzard BG, Anderson J., Babiker A., et al. BHIVA Treatment Guidelines Writing Group.British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med.2008;9(8):563-608.
14.
Sungkanuparph S., Anekthananon T., Hiransuthikul N., et al. Thai AIDS Society.Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai. 2008;91(12):1925-1935.
15.
Mocroft A., Phillips AN, Miller V., et al. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS. 2001 ;15(2):201-209.
16.
Castelnuovo B., John L., Lutwama F., et al. Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care.2009;8(1):52-59.
17.
Pujades-Rodríguez M., O’Brien D., Humblet P., Calmy A.Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS. 2008;22(11):1305-1312.
18.
Meltzer D., Manning WG, Morrison J., et al. Effects of physician experience on costs and outcomes on an academic general medicine service: results of a trial of hospitalists. Ann Intern Med. 2002;137(11):866-874.
19.
Kitahata MM , Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EHPhysician’s experience with the acquired immunodeficiency syndrome as a factor in patient’s survival. N Engl J Med. 1996;334(24):701-706.
20.
Schneider JA , Zhang Q., Auerbach A., et al. Do hospitalists or physicians with greater inpatient HIV experience improve HIV care in the era of highly active antiretroviral therapy? Results from a multicenter trial of academic hospitalists . Clin Infect Dis. 2008; 46(7):1085-1092.
21.
Mee P., Fielding KL, Charalambous S., Churchyard GL, Grant ADEvaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008;22(15):1971-1977.
22.
Kantor R., Diero L., Delong A., et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings . Clin Infect Dis.2009;49(3):454-462.
23.
Cozzi-Lepri A., Phillips AN, Martinez-Picado J., et al. EuroSIDA Study Group.Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis. 2009;200(5):687-697.
24.
Soria A., Porten K., Fampou-Toundji JC, et al. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Antivir Ther.2009;14(3):339-347.
25.
Oyomopito R. , Lee MP, Phanuphak P., et al. On behalf of The TREAT Asia HIV Observational Database.Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD). HIV Med. 2010;11(8):519-529.
26.
Clevenbergh P., Boulmé R., Kirstetter M., Dellamonica P.Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients. HIV Med . 2004;5(4):284-288.
27.
Palella FJ, Jr, Armon C., Buchacz K., et al. HOPS (HIV Outpatient Study) Investigators.The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2009 ;151(2):73-84.
28.
Egger S., Petoumenos K., Kamarulzaman A., et al. Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr.2009;50(5):513-520.
29.
Turner BJAdherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis. 2002;185(2): S143-S151.
30.
Ahoua L., Guenther G., Pinoges L., et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda . BMC Infect Dis.2009;9(6):81.
31.
Bongiovanni M., Bini T., Cicconi P., et al. Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir. AIDS Res Hum Retroviruses. 2006;22(1):132-138.
32.
Shafran SD, Mashinter LD, Roberts SEThe effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations . HIV Med. 2005;6(6):421-425.
33.
Gutiérrez F., Padilla S., Navarro A., et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr. 2003 ;33(5):594-600.
34.
Smith JH, Martin GJ, Decker CFHyperlipidemia associated with the use of protease inhibitors. Clin Infect Dis. 2000;31(1):207-208.
